The functional activity of C14orf118 is influenced by various compounds that modulate intracellular signaling pathways. One such mechanism involves the elevation of cyclic AMP (cAMP) within the cell. Certain compounds directly stimulate adenylyl cyclase or inhibit phosphodiesterases, leading to increased cAMP levels, which in turn activate protein kinase A (PKA) and other cAMP-responsive elements. This cascade of events is crucial for the regulation of numerous cellular processes, and the modulation of C14orf118 is likely tied to these cAMP-dependent pathways. Similarly, other chemicals act as ionophores, increasing the intracellular concentration of calcium ions. As calcium signaling is pivotal in a myriad of cellular functions, including the regulation of protein activities through calcium-dependent kinases and phosphatases, these changes in calcium levels can indirectly affect the activity of C14orf118 by activating or inhibiting these calcium-responsive elements.
In addition to the modulation of cAMP and calcium levels, the activity of C14orf118 can be influenced by alterations in protein phosphorylation states. Certain inhibitors target phosphatases, leading to a general increase in protein phosphorylation, which could involve the phosphorylation state of C14orf118 if it is a phosphorylation target. Moreover, activators of protein kinase C can induce changes in protein activities through PKC-mediated signaling pathways, potentially impacting the functional state of C14orf118. Other compounds induce cellular stress responses, activating a variety of stress-activated protein kinases that can have wide-ranging effects on cellular proteins, including those like C14orf118 that may be involved in the cellular stress response.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective inhibitor of phosphodiesterases, raises cAMP by preventing its breakdown, potentiating cAMP-related activation of C14orf118. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selective phosphodiesterase-4 inhibitor, leads to an increase in cAMP concentrations, potentially enhancing C14orf118 activity linked to cAMP signaling. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Binds to and activates its G-protein-coupled EP receptors, can increase intracellular cAMP, thereby influencing C14orf118 activity via downstream signaling. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Activates stress-activated protein kinases, which could in turn regulate C14orf118 activity as part of the cellular stress response. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Calcium ionophore that raises intracellular calcium levels, potentially modulating C14orf118 activity through calcium-dependent signaling mechanisms. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels of proteins, potentially including C14orf118 if it is a substrate. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activator of protein kinase C (PKC) that could modulate C14orf118 activity through PKC-dependent phosphorylation pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A calcium ionophore, elevating intracellular calcium and potentially affecting C14orf118 activity through calcium-mediated signaling processes. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Membrane-permeable cAMP analog that directly activates cAMP-dependent pathways, possibly leading to increased activity of C14orf118. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Inhibits phosphodiesterase type 5, elevating cGMP levels, which might cross-activate cAMP pathways and thereby influence C14orf118 activity. | ||||||